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ABSTRACT
Introduction: The World Health Organization (WHO) recommends one single dose of 
the Yellow Fever (YF) vaccine based on studies of antibody persistency in healthy adults. We 
assessed the prevalence and titers of YF virus neutralizing antibodies in previously vaccinated 
persons aged ≥ 60 years, in comparison to younger adults. We also evaluated the correlation 
between antibody titers and the time since vaccination among participants who received one 
vaccine dose, and the seropositivity among participants vaccinated prior to or within the past 
10 years. Methods: previously vaccinated healthy persons aged ≥ 18 years were included. YF 
virus neutralizing antibody titers were determined by means of the 50% Plaque Reduction 
Neutralization Test. Results: 46 persons aged ≥ 60 years and 48 persons aged 18 to 59 years 
were enrolled. There was no significant difference in the prevalence of YF virus neutralizing 
antibodies between the two groups (p = 0.263). However, titers were significantly lower in 
the elderly (p = 0.022). There was no correlation between YF virus neutralizing antibody 
titers and the time since vaccination. There was no significant difference in seropositivity 
among participants vaccinated prior to or within the past 10 years. Conclusions: the clinical 
relevance of the observed difference in YF virus neutralizing antibody titers between the 
two groups is not clear. 
KEYWORDS: Elderly. Immunization. Neutralizing antibody. Seroprevalence. Yellow fever 
vaccine. 
INTRODUCTION
Yellow fever (YF) is caused by a Flavivirus transmitted by mosquitos’ bites. In 
the sylvatic cycle, the virus is transmitted by Haemagogus spp and Sabethes spp, 
and in the urban cycle by Aedes spp. It is a severe acute disease with no available 
antiviral treatment, and vaccination is the most important preventive measure. Two 
types of live attenuated vaccines are available, 17DD and 17D-204, both derived 
from the strain 17D1. 
YF disease is an important public health problem in Brazil. During the 2000s 
the transmission risk area has expanded, causing YF outbreaks in areas that were 
previously free of YF virus circulation in the South and Southeast of the country2,3,4. 
Nowadays, YF vaccine is recommended for those living in such regions, including 
the elderly that should receive their primary immunization. 
The World Health Organization (WHO) has recently recommended a single 
lifetime dose of YF vaccine, based on the evidence of long-term immunity5. The 
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Brazilian Ministry of Health currently recommends two 
doses of YF vaccine: children under the age of four living 
in endemic areas should receive the first dose at 9 months, 
and a second dose at four years of age; persons older 
than four years should receive two vaccine doses with 
a 10 year-interval6. The YF 17DD vaccine produced by 
Biomanguinhos (Fundação Oswaldo Cruz, Rio de Janeiro) 
is used in Brazil. 
The elderly population is increasing in Brazil and 
worldwide. Considering that aging is associated with 
effects on immunity and vaccine response, particularly 
in primary vaccination7,8, studies to assess the duration of 
protection conferred by the YF vaccine in this population 
are necessary. 
This study aimed to evaluate the prevalence and titers 
of YF virus neutralizing antibodies among previously 
vaccinated persons aged ≥ 60 years as compared to 
younger adults. We also tested the correlation between 
YF virus neutralizing antibody titers and the time since 
vaccination among adults who received just one dose of 
the YF vaccine. 
MATERIALS AND METHODS
Study Population 
This study was conducted at the Reference Center for 
Special Immunobiologicals (Centro de Referência para 
Imunobiológicos Especiais, CRIE) of the Hospital das 
Clínicas da Faculdade de Medicina da Universidade de 
São Paulo (HC-FMUSP), in São Paulo city, a non-endemic 
area for YF transmission. We included healthy persons 
aged ≥ 18 years who had previously received the YF 
vaccine, regardless of the number of doses and the time 
since last vaccination. Healthcare workers and persons 
who came to CRIE to receive any vaccine were invited 
to participate. Pregnant women, immunocompromised 
patients and those with acute febrile conditions were 
excluded. All the subjects were submitted to two HIV 
rapid tests (Abbott DetermineTM HIV-1/2 and SD Bioline 
HIV 1/2 fast 3.0) and all non-menopausal women were 
tested for pregnancy (chorionic gonadotropin test in urine, 
ABONTM hCG). Persons with positive or indeterminate 
tests were excluded. All participants signed an informed 
consent form. The study was approved by the HC-FMUSP 
Ethics Committee.
Participants were divided into two groups: persons 
aged 60 years and more (Group 1) and those aged from 
18 to 59 years (Group 2). Data on age, ethnicity, gender, 
number of previous YF vaccine doses and date of the last 
YF vaccination were collected.
YF virus neutralizing antibody measurements
YF virus neutralizing antibody was measured using the 
Plaque Reduction Neutralization Test (PRNT). The PRNT 
titer was defined as the reciprocal of the last serum dilution 
that reduced the number of plaques by 50% (PRNT50). 
The test was performed in the Virological Technology 
Laboratory, Bio-Manguinhos, Fundação Oswaldo 
Cruz, as previous described9. In that study, the value of 
2.9 log10 mIU/ mL (794 mIU/ mL or 1:50) provided the best 
combination of sensitivity and specificity for the PRNT50 
test, in the ROC curve9. Results ≥ 794 mIU/ mL (equivalent 
to 2.9 log10 mIU/ mL) were considered seropositive and 
results < 794 mIU/ mL were considered seronegative. 
Statistical analyses
A Microsoft Excel database (Microsoft Corp., 
Redmond, Washington, USA) was built and statistical 
analysis was performed using SPSS for Windows version 
15.0 (SPSS Inc., Chicago, IL, USA) and Epi Info 7 (CDC, 
Atlanta, GA, USA).
Descriptive analyses of the medians, means, standard 
deviations and percentages were used to establish the 
participants demographic and clinical characteristics. YF 
virus neutralizing antibody titers were log10-transformed 
for analysis. The chi-square test was used to compare 
the frequencies of the categorical variables (e.g., gender, 
ethnicity, number of YF vaccine doses previously taken and 
YF seropositivity between the groups, and the Student’s 
t-test or Mann-Whitney test were used to compare the 
continuous variables (time since vaccination, and YF virus 
neutralizing antibody titers), as appropriate.
Correlation between YF neutralizing antibody titers 
and the time since vaccination in participants who had 
previously received only one dose of YF vaccine was 
described by the Spearman coefficient. The Fisher’s Exact 
test was applied to compare the seroprevalence of YF 
antibodies in participants who had received just one vaccine 
dose within ten years and more than ten years before.
Statistical tests were performed with a significance 
level of 5%. 
RESULTS
From November 2010 to February 2013, 94 volunteers 
were included, 46 in Group 1 (≥ 60 years old) and 
48 in Group 2 (18 to 59 years). Table 1 shows the 
participants demographic characteristics and the history 
of YF vaccination. There was no statistically significant 
difference between the study groups regarding gender 
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(p = 0.204), ethnicity (p = 0.131), number of previous 
YF vaccine doses (p = 0.146) and time elapsed since the 
last vaccination (p = 0.108). Four participants could not 
provide a vaccination document (two in each group), but 
the information was considered reliable. None of them 
lived in endemic areas at the time they were enrolled in the 
study; and three of the four knew the exact circumstances 
of vaccination (year and motivation).
Table 2 shows the frequency of YF seropositivity 
and the log10-transformed Geometric Mean Titer (GMT) 
of YF virus neutralizing antibodies in both groups. The 
difference in seropositivity between the groups was not 
statistically significant. However, log10-transformed 
antibody titers were significantly lower in the elderly 
group (p = 0.022). 
Nine subjects were seronegative for YF (< 794 mIU/ mL), 
six in Group 1 (mean = 560 mIU/ mL) and three in Group 
2 (of whom two had PRNT50 titers below the limit of 210 
mIU/ mL). All nine subjects had previous documented 
YF vaccination (Table 3). Six participants (five in Group 
1 and one in Group 2) had been vaccinated within the last 
10 years (mean time since vaccination = 26.7 months and 
16.3 months, respectively), whereas three subjects (one in 
Group 1 and two in Group 2) had been vaccinated more 
than 10 years before enrollment (mean = 145.4 months and 
141.6 months, respectively). One participant (Group 1) had 
previously received two doses of YF vaccine and one could 
not remember how many doses she had received. 
Twenty-four participants (10 in Group 1 and 14 in 
Group 2) had received the YF vaccine more than 10 years 
before enrollment. Among those, three were seronegative 
for YF, one in Group 1 (who did not remember how many 
YF vaccine doses she had previously received) and two in 
Group 2 (both had received only one YF vaccine dose). 
Considering all the subjects who had received a single 
dose (n = 59), there was no correlation between the time 
elapsed since vaccination and GMT (ρSpearman= -0.0804, 
p = 0.56) as shown in Figure 1. 
There was also no statistically significant difference in 
seropositivity among participants of all ages who received 
Table 1 - Demographic characteristics and history of yellow fever vaccination of participants aged 60 years or more (Group 1) and 
under-60 years (Group 2).
Group 1 (≥ 60 y) 
n=46 
no (%)
Group 2 (18 – 59 y) 
n=48  
no (%)
p-value
Age 
Mean (SD) 
Median (min – max)
70.0 (6.5) 
68.5 (60 – 85)
35.6 (9.9) 
33.0 (20 – 58) -
Gender 
Female 30 (65.2) 37 (77.1) 0.204
Race 
Caucasian  
African 
Asian  
Indigenous
30 (65.2) 
10 (21.7) 
5 (10.9) 
1(2.2)
38 (79.2) 
6 (12.6) 
4 (8.3) 
0 (0.0)
0.131*
Number of previous doses of Yellow Fever vaccine (n =76)**
1 
≥2 
Unknown (≥1)
23 (50.0) 
10 (21.7) 
13 (28.3)
36 (75.0) 
7 (14.6) 
5 (10.4)
0.146
Time elapsed since last dose (months) (n=93)#
Mean (SD) 
Median (min – max)
60.9 (52.3) 
40.0 (3.4 – 232.3)
80.2 (57.1) 
69.3 (1.7 – 246.3)
0.108 
Age at last vaccination (n=93)#
Mean (SD) 
Median (min-max)
65.3 (7.0) 
64.9 (50.0 – 83.1)
29.3 (9.8) 
27.6 (10.6 – 54.5)
Time elapsed since last vaccination
<10 years 
>10 years
36 (78.3) 
10 (21.7)
34 (70.8)  
14 (29.2)
*Analysis comparing caucasian and non-caucasian persons. ** Analysis excluded persons that did not know how many doses they 
received. # One person was excluded of the analysis because she did not know when she received the vaccine.
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a single dose of YF vaccine within the last 10 years (n = 46) 
and those immunized more than 10 years before enrollment 
(n = 13, p = 0.9723).
DISCUSSION
The present study evaluated 94 subjects previously 
vaccinated for YF to evaluate the antibody seropositivity in 
the elderly (≥ 60 years of age) in comparison with younger 
adults (18-59 years of age). YF virus neutralizing antibody 
titers were measured by PRNT50, a sensitive and specific 
test to quantify YF virus neutralizing antibodies10. Older 
and younger adults had similar time elapsed since the 
last vaccination, and seropositivity was not significantly 
different between the groups. However, log10-transformed 
titers of neutralizing antibodies were slightly lower 
among older adults compared to the younger ones 
(3.64 vs. 3.77 log10 mIU/ mL, p = 0.022). The clinical 
relevance of this difference is unclear, since titers in both 
groups are high; it is unlikely that this difference will result 
in altered immunity to YF. 
Aging of the human immune system, or immuno-
senescence, is characterized by changes in the innate 
and adaptive immune responses including decreased 
hematopoietic stem cells proliferation capacity, reduction 
Table 2 - Seroprevalence and log-transformed geometric mean titers of Yellow Fever (YF) neutralizing antibody (Ab) measured by 
Plaque Reduction Neutralization Test (PRNT50) among participants aged 60 years or more (Group 1) and under-60 years (Group 2).
Group 1 (≥ 60 y) 
n=46 
no (%)
Group 2 (18 – 59 y) 
n=48  
no (%)
p-value
Seroprevalence (neutralizing Ab, mIU/mL)# 
Positive
Negative
40 (87.0) 
6 (13.0)
45 (93.8) 
3 (6.3) 0.263
YF neutralizing Ab titer (log10mIU/mL) (n=88)*
Mean (SD, CI 95%) 
Median (min – max)
3.44 (0.43, 3.35-3.53) 
3.48 (2.38 – 4.28)
3.64 (0.36, 3.56-3.71) 
3.67 (2.77 – 4.27) 0.022
# Cutoff=794mIU/mL, equivalent of 2.9 log10mIU/mL.
*Participants without exact titer were excluded from this analysis (four with results above the upper limit of the test and two below 
the lower limit of the test). 
Table 3 - Characteristics of the subjects seronegative for yellow fever.
Subject Age / Age at the moment 
of vaccination Gender
Number of previous 
doses
Time elapsed since last 
dose (months)
1 68 / 64.89 F 1 40.23
2 81 / 78.25 F 1 40.03
3 69 / 68.75 F 2 3.40
4 68 / 66.46 M 1 24.30
5 65 / 63.22 F 1 22.33
6 70 / 58.73 F Unknown (≥ 1) 145.37
7 45 / 44.10 F 1 16.63
8 37 / 25.05 F 1 141.87
9 33 / 21.16 F 1 141.40
Figure 1 - Scatter plot of Yellow Fever neutralizing antibody 
titers (log10 mIU/mL) measured by 50% Plaque Reduction 
Neutralization Test (PRNT50) and time elapsed since vaccination 
in participants who had received just one dose of YF vaccine. 
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in lymphoid precursors cells and increase in myeloid 
precursors cells. Consequently, older subjects usually 
present with quantitative and qualitative reduction in 
antigen presenting cells. Additionally, the adaptive 
response is affected by aging through thymus involution, 
with lower populations of naïve T and B lymphocytes 
and predominance of memory and effectors cells. These 
changes lead to a reduction in cell receptors repertoire 
and a decreased responsiveness to new antigens, such as 
primary vaccination7,8. 
Our results of similar seropositivity between the 
two groups is compared to other studies that evaluated 
seroconversion after YF vaccination in the elderly. Roukens 
et al.11 compared YF virus neutralizing antibody titers 
between elderly (from 60 to 81 years, median 66 years) and 
a younger group (from 18 to 28 years, median 21 years) 
before, and 10 and 28 days after YF vaccination. They used 
a variation of the PRNT method and titers ≥ 500 mIU/mL 
were considered protective. Ten days after vaccination, 
50% of older adults were seropositive, as compared to 77% 
of the younger group and GMT was 2.9 IU/mL lower in 
the elderly group. However, 28 days after vaccination, the 
difference between the two groups disappeared, suggesting 
that the elderly have a slower response but, ultimately, a 
response that is quantitatively similar to the younger group. 
Long-term persistency of protection was not evaluated in 
this study. 
Monath et al.12 evaluated the immunogenicity of a 
single dose of YF vaccine in younger (18 to 44 years old) 
and older (≥ 60 years old) adults, using a constant serum-
varying virus plaque-reduction test. A log10 neutralization 
index (LNI ≥ 0.7 thirty days after vaccination was 
considered protective. There was no difference between the 
two study groups. These studies showed no difference in 
seroconversion between the elderly and young persons, but 
they did not evaluate the long-term antibody persistence. 
Gotuzzo et al. performed a systematic review of efficacy, 
duration of protection and the need of booster doses of 
YF vaccine13. They found a long-term persistency of YF 
antibody in healthy persons, with > 90% seropositivity 
at 20 years after vaccination, and up to 80% of antibody 
persistency at 35 years after vaccination. Only one study 
included in this review14 evaluated persons ≥ 60 years old, 
who had received the vaccine ≥ 10 years before enrollment 
and had some contraindication to be revaccinated (n = 84), 
showing seropositivity in 95.2%. This result contrasts with 
the 87% seropositivity found in our study. Another Brazilian 
study evaluated previously vaccinated persons aged 18 to 
83 year-old, describing 93.9% of seropositivity 1 to 4 years 
after vaccination; 83.1%, 5 to 9 years; 76.1%, 10 to 11 years; 
and 85.3%, ≥ 12 years15. 
In our study, there was no statistically significant 
difference in seropositivity between the subjects who had 
received a single dose of YF vaccine within the last 10 years 
(median 39.8 months) and more than 10 years (median 
149.3 months) before enrollment. This result is similar 
to those found in other studies that evaluated antibody 
persistence16,17,18. However, we had few participants who 
had received a single vaccine dose (n = 59) and that received 
the YF vaccine more than 10 years before enrollment 
(n = 23).
Nine out of 94 participants were seronegative for YF. 
This is a relevant finding, suggesting that a significant 
proportion of vaccinees are actually not protected against 
YF. Six of the nine seronegative subjects were vaccinated 
less than ten years prior to enrollment suggesting failure to 
seroconvert. There were 5 seronegative among 36 (13.89%) 
persons aged more than 60 years and only one seronegative 
among 34 (2.94%) persons aged less than 60 years. In spite 
of the small sample, this finding suggests that the elderly 
may have a higher rate of failure to seroconvert after 
vaccination. Accordingly, cases of vaccine failure have 
been reported. In Brazil, Tuboi et al.19 reviewed five cases 
of YF in subjects with documented vaccination, leading to 
two deaths. They were between the ages of 17 to 62 years 
and the time elapsed since vaccination varied from 5 to 62 
months. Gotuzzo et al.13 described five additional cases, 
with three deaths, in persons who had been vaccinated from 
15 months to five years before the disease development. In 
both studies, the short time between vaccination and disease 
suggests primary vaccine failure.
Seroconversion rates after vaccination, waning 
immunity and primary vaccine failure are important factors 
to be considered when recommending a single dose of 
YF vaccine, particularly in endemic areas. Our study did 
not find any correlation between the time elapsed since 
vaccination and YF virus neutralizing antibody titers among 
subjects who had received a single dose of YF vaccine. 
This study has some limitations. We had a small sample 
size. We cannot exclude that exposure to wild YF plays a 
role as a natural booster, preventing the reduction of YF virus 
neutralizing antibody titers over time, although none of the 
subjects lived in endemic areas. We cannot rule out that some 
participants received more vaccine doses than reported, since 
large vaccine campaigns have been conducted in the country 
in recent years, and we expect the vaccine documentation 
to be imperfect in this context. In the elderly group, eight 
(17.4%) were vaccinated before the age of 60, and it was not 
possible to analyze separately the subjects who had received 
the vaccine before and after 60 years of age due to the small 
sample size. We included four subjects without the vaccine 
documentation because the information given was considered 
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reliable and losing the vaccine document is very frequent. 
All four were seropositive for YF antibody. Other studies 
have also included persons with only the verbal report of 
vaccination14,16. 
In conclusion, this study found no difference in 
seropositivity between elderly and younger subjects and 
no correlation between the time since vaccination and 
YF virus antibody titers. Even though, the finding of nine 
seronegative subjects, six of them aged more than 60 years, 
may represent failure to seroconvert. Our findings support 
the Health Ministry decision of recommending two doses 
of YF vaccine instead of the WHO recommendation of a 
single vaccine dose. More studies including the elderly, 
persons with comorbidities and immunocompromised 
patients living in endemic areas are necessary to address 
whether response to YF vaccination is weaker or of shorter 
duration in these population groups. 
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